The UCCRC Transgenic Mouse/Embryonic Stem Cell Facility provides comprehensive genetic engineering services to alter the genome of the laboratory mouse. The UCCRC has many investigators who use mouse models as their primary tool of analysis, as well as a multitude of additional investigators who require the occasional mouse model in their studies of the causes and treatment of cancer. The generation and maintenance of transgenic animals through the microinjection of singlecelled mouse embryos, and the generation of genetically modified mice through the use of ES cells require specialized technical personnel. Furthermore, such efforts necessitate the acquisition of an array of devoted equipment. Thus, the availability of a shared facility greatly reduces research costs for the individual investigators of the UCCRC. The existence of this facility also greatly increases the accessibility of genetic engineering technology to investigators with limited related experience. The UCCRC Transgenic Mouse/Embryonic Stem Cell Facility was established in 1991, and has been tremendously productive and successful;the range of services provided has expanded considerably since its founding. Nine services are provided by the Transgenic Mouse/Embryonic Stem Cell Facility: (1) transgenic mouse production from founder through F1 Stage;(2) ES cell technology mouse production;(3) ES cell gene targeting and culturing;(4) mouse embryonic feeder (MEF) cell production; (5) Timed pregnancies of various strains and lines of mice;(6) embryo rederivation;(7) ES cell line development;(8) various breeding services and GEM model line maintenance;and (9) DMA preparation from ES cell lines for the construction of a gene targeting construct. In addition to the technical services, the Facility also offers assistance with the design of studies that require mouse molecular genetics and an annual course in Mouse Handling and Breeding. This course covers information regarding analysis and handling of the mice once the Facility has generated them, as well as general breeding and handling procedures for mice. In providing these comprehensive services, the UCCRC Transgenic Mouse/Embryonic Stem Cell Facility has generated mouse models that have led to advances in our understanding of cancer, including cancers of the breast, skin, colon, brain and hematopoietic system.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-35
Application #
8105359
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2010-04-01
Budget End
2011-03-31
Support Year
35
Fiscal Year
2010
Total Cost
$263,043
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Luke, Jason J; Lemons, Jeffrey M; Karrison, Theodore G et al. (2018) Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol 36:1611-1618
Wang, Amy Y; Weiner, Howard; Green, Margaret et al. (2018) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. J Hematol Oncol 11:4
Sample, Ashley; He, Yu-Ying (2018) Mechanisms and prevention of UV-induced melanoma. Photodermatol Photoimmunol Photomed 34:13-24
Jeong, Choongwon; Witonsky, David B; Basnyat, Buddha et al. (2018) Detecting past and ongoing natural selection among ethnically Tibetan women at high altitude in Nepal. PLoS Genet 14:e1007650
Wang, Xin; Wu, Xingye; Zhang, Zhonglin et al. (2018) Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway. Sci Rep 8:17914
Brown, Hailey M; Biering, Scott B; Zhu, Allen et al. (2018) Demarcation of Viral Shelters Results in Destruction by Membranolytic GTPases: Antiviral Function of Autophagy Proteins and Interferon-Inducible GTPases. Bioessays 40:e1700231
Karrison, Theodore; Kocherginsky, Masha (2018) Restricted mean survival time: Does covariate adjustment improve precision in randomized clinical trials? Clin Trials 15:178-188
An, Ningfei; Khan, Saira; Imgruet, Molly K et al. (2018) Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood 131:2682-2697
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74

Showing the most recent 10 out of 668 publications